The present disclosure refers to topical pharmaceutical bases that possess scar healing properties. Further, these topical pharmaceutical bases are proposed for treating skin conditions, such as, for example keloids, hypertrophic scars, wounds, and burns, among others. The topical pharmaceutical bases include Amazonian oils and resins, such as pracaxi oil and breu-branco resin. The synergistic effect of pracaxi oil combined with breu-branco resin results in a highly effective scar and wound treatment. Suitable active pharmaceutical ingredients (APIs) can be incorporated to the topical pharmaceutical bases to formulate topical pharmaceutical compositions, which improve healing effects. The synergistic effect provided by the combination of pracaxi oil and breu-branco resin enables lower dosage requirements of the associated APIs when topical pharmaceutical compositions are employed for treating skin conditions.

The present disclosure refers to topical pharmaceutical bases that possess scar healing properties. Further, these topical pharmaceutical bases are proposed for treating skin conditions, such as, for example keloids, hypertrophic scars, wounds, and burns, among others. The topical pharmaceutical bases include Amazonian oils and resins, such as pracaxi oil and breu-branco resin. The synergistic effect of pracaxi oil combined with breu-branco resin results in a highly effective scar and wound treatment. Suitable active pharmaceutical ingredients (APIs) can be incorporated to the topical pharmaceutical bases to formulate topical pharmaceutical compositions, which improve healing effects. The synergistic effect provided by the combination of pracaxi oil and breu-branco resin enables lower dosage requirements of the associated APIs when topical pharmaceutical compositions are employed for treating skin conditions.

The present invention relates to an immunologically active phyto-mixture comprising at least one plant extract selected from the family a) Asteraceae, b) Verbenaceae, and/or c) Burseraceae, preferably at least one plant extract from the genus a) Bidens, b) Stachytarpheta, and/or c) Bursera. Particularly preferred species include a) Bidens alba, Bidens pilosa, b) Stachytarpheta jamaicensis, Stachytarpheta cayennensis, Stachytarpheta indica, and/or c) Bursera simaruba, Bursera microphylla, Bursera glabrifolia. The phyto-mixture optionally comprises d) at least one further biologically active plant extract, such as Aloe vera and/or Stemodia maritima. The afore-mentioned phyto-mixture according to the invention exhibits good antimicrobial and anti-inflammatory efficiency and is particularly suitable for prevention and treatment of efflorescences. Therefore, the present invention also relates to a preparation for oral and topical administration for prevention and treatment of efflorescences of the skin and the mucous membrane.

The present invention relates to an immunologically active phyto-mixture comprising at least one plant extract selected from the family a) Asteraceae, b) Verbenaceae, and/or c) Burseraceae, preferably at least one plant extract from the genus a) Bidens, b) Stachytarpheta, and/or c) Bursera. Particularly preferred species include a) Bidens alba, Bidens pilosa, b) Stachytarpheta jamaicensis, Stachytarpheta cayennensis, Stachytarpheta indica, and/or c) Bursera simaruba, Bursera microphylla, Bursera glabrifolia. The phyto-mixture optionally comprises d) at least one further biologically active plant extract, such as Aloe vera and/or Stemodia maritima. The afore-mentioned phyto-mixture according to the invention exhibits good antimicrobial and anti-inflammatory efficiency and is particularly suitable for prevention and treatment of efflorescences. Therefore, the present invention also relates to a preparation for oral and topical administration for prevention and treatment of efflorescences of the skin and the mucous membrane.

The present invention relates to an immunologically active phyto-mixture comprising at least one plant extract selected from the family a) Asteraceae, b) Verbenaceae, and/or c) Burseraceae, preferably at least one plant extract from the genus a) Bidens, b) Stachytarpheta, and/or c) Bursera. Particularly preferred species include a) Bidens alba, Bidens pilosa, b) Stachytarpheta jamaicensis, Stachytarpheta cayennensis, Stachytarpheta indica, and/or c) Bursera simaruba, Bursera microphylla, Bursera glabrifolia. The phyto-mixture optionally comprises d) at least one further biologically active plant extract, such as Aloe vera and/or Stemodia maritima. The afore-mentioned phyto-mixture according to the invention exhibits good antimicrobial and anti-inflammatory efficiency and is particularly suitable for prevention and treatment of efflorescences. Therefore, the present invention also relates to a preparation for oral and topical administration for prevention and treatment of efflorescences of the skin and the mucous membrane.

The present disclosure refers to topical pharmaceutical bases that possess anti-inflammatory properties. Further, these topical pharmaceutical bases are proposed for treating inflammatory disorders, such as swollen tissues within joints and muscles, and the like. The topical pharmaceutical bases include Amazonian oils and resins, such as pracaxi oil and breu-branco resin. The synergistic effect of pracaxi oil combined with breu-branco resin results in a highly effective anti-inflammatory treatment. Suitable active pharmaceutical ingredients (APIs) can be incorporated to the topical pharmaceutical bases to formulate topical pharmaceutical compositions, which improve anti-inflammatory effects. The synergistic effect provided by the combination of pracaxi oil and breu-branco resin enables lower dosage requirements of the associated APIs when topical pharmaceutical compositions are employed for treating inflammatory disorders.

The present disclosure refers to topical pharmaceutical bases that possess anti-inflammatory properties. Further, these topical pharmaceutical bases are proposed for treating inflammatory disorders, such as swollen tissues within joints and muscles, and the like. The topical pharmaceutical bases include Amazonian oils and resins, such as pracaxi oil and breu-branco resin. The synergistic effect of pracaxi oil combined with breu-branco resin results in a highly effective anti-inflammatory treatment. Suitable active pharmaceutical ingredients (APIs) can be incorporated to the topical pharmaceutical bases to formulate topical pharmaceutical compositions, which improve anti-inflammatory effects. The synergistic effect provided by the combination of pracaxi oil and breu-branco resin enables lower dosage requirements of the associated APIs when topical pharmaceutical compositions are employed for treating inflammatory disorders.

The present disclosure refers to topical pharmaceutical bases that possess anti-inflammatory properties. Further, these topical pharmaceutical bases are proposed for treating inflammatory disorders, such as swollen tissues within joints and muscles, and the like. The topical pharmaceutical bases include Amazonian oils and resins, such as pracaxi oil and breu-branco resin. The synergistic effect of pracaxi oil combined with breu-branco resin results in a highly effective anti-inflammatory treatment. Suitable active pharmaceutical ingredients (APIs) can be incorporated to the topical pharmaceutical bases to formulate topical pharmaceutical compositions, which improve anti-inflammatory effects. The synergistic effect provided by the combination of pracaxi oil and breu-branco resin enables lower dosage requirements of the associated APIs when topical pharmaceutical compositions are employed for treating inflammatory disorders.

An antiviral agent contains at least one of rosin, copal, and shellac. The antiviral agent may be composed of at least one of copal and shellac, and rosin. The agent may contain 0.02 to 2.0 parts by mass of the shellac with respect to 1.0 part by mass of the rosin.

An antiviral agent contains at least one of rosin, copal, and shellac. The antiviral agent may be composed of at least one of copal and shellac, and rosin. The agent may contain 0.02 to 2.0 parts by mass of the shellac with respect to 1.0 part by mass of the rosin.